With the stock down sharply since April, is Allergan finally ready to rebound?
That's a pressing question for Jim Cramer.
"I've liked this stock for a long time not only for its breast implants, wrinkle-removers, and eyelash enlargers, but also for its more traditional drug business focused on eye care and migraines," Cramer said.
In April 2012, Cramer called Allergan 'a fabulous growth stock.'
But even the most fabulous stocks can hit a rough patch.
Shares have been under pressure for the past several months after Allergan said that Darpin, a highly anticipated drug, had encountered delays.
"We also learned that Allergan's second biggest drug, Restasis for dry eye, might face generic competition sooner than expected," Cramer said.
Developments sent investors running for the exits.